Shares of Amgen Inc. AMGN inched 0.24% higher to $264.00 Monday, on what proved to be an all-around favorable trading session ...

The most recent trading session ended with Amgen (AMGN) standing at $264, reflecting a +0.24% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.73%.

We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Amgen's leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict ...

StockNews.com lowered shares of Amgen (NASDAQ:AMGN – Free Report) from a strong-buy rating to a buy rating in a research ...

Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers ...

Shares of Amgen Inc. AMGN slumped 0.21% to $265.95 Tuesday, on what proved to be an all-around dismal trading session for the ...

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly ...

Amgen, a biotechnology company, announced last week that it will invest $1 billion in expanding its manufacturing facility in ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

UBS analyst Trung Huynh says Novo Nordisk’s CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly and Amgen . CagriSema achieved an ave ...